These ten mid-cap shares have been the very best performers within the final week. Are they in your portfolio?
- Akero Therapeutics, Inc. AKRO shares surged 106.57% after the corporate reported preliminary Week 96 outcomes from its SYMMETRY Section 2B examine of Efruxifermin. A number of analysts boosted the value forecast.
- Surgical procedure Companions, Inc. SGRY inventory elevated 25.44% after the corporate introduced it obtained a non-binding acquisition proposal from Bain Capital Non-public Fairness.
- Flagstar Monetary, Inc. FLG shares rose 24.40% fter the corporate reported better-than-expected monetary outcomes. Barclays analyst Jared Shaw maintained an Obese and raised the value forecast from $13 to $14.
- Nextracker Inc. NXT shares escalated 22.98% after the corporate reported better-than-expected 2025 fiscal-year third-quarter monetary outcomes and raised its steering. A number of analysts revised the value forecast.
- Brighthouse Monetary, Inc. BHF shares are up 21.76% following a report suggesting that the corporate is exploring a possible sale. Barclays analyst Alex Scott upgraded the corporate from Equal-Weight to Obese and raised the value forecast from $52 to $85.
- Brinker Worldwide, Inc. EAT inventory upped 21.72% after the corporate reported better-than-expected second-quarter outcomes and several other analysts modified their worth forecasts.
- Hims & Hers Well being, Inc. HIMS shares have been up 20.76%.
- Oshkosh Company OSK shares surged 19.38% after the corporate beat fourth-quarter estimates, initiated FY25 EPS steering above expectations, and raised its quarterly dividend by 11%. Analysts boosted the value forecast on the inventory.
- Kingsoft Cloud Holdings KC inventory upped 16.50%, most likely as a result of Lunar New 12 months, latest AI developments in China and authorities efforts to spice up markets.
- Viavi Options Inc. VIAV inventory jumped 14.78% after the corporate reported better-than-expected second-quarter monetary outcomes.
Learn Subsequent:
Picture through Shutterstock
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
